Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen

Journal of Infectious Diseases

Volumn 183, Issue 2, 2001, Pages 303-312

  Jones, Trevor R ^a   Narum, David L ^c   Gozalo, Alfonso S ^a   Aguiar, Joao ^a   Fuhrmann, Steven R ^c   Liang, Hong ^c   Haynes, J David ^a,b   Moch, J Kathleen ^a,b   Lucas, Carmen ^a   Magill, Alan J ^a,d   Hoffman, Stephen L ^a   Sim, B K L ^c  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c EntreMed   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; PLASMID DNA; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; AOTUS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MALARIA; MALE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANEMIA; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; AOTUS TRIVIRGATUS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 20244384380     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317933     Document Type: Article

References (39)

1. Research toward vaccines against malaria
2. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?
3. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites
4. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion
5. A family of erythrocyte binding proteins of malaria parasites
6. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum
7. Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175
8. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
9. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
10. Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol
11. A primeboost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naive and infection-primed mice
12. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
13. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
14. Induction of immune responses to HIV-1 by canary pox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
15. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
16. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
17. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
18. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
19. Plasmodium falciparum EBA-175 region II DNA vaccination induces biologically active antibodies
20. Plasmodium falciparum strain-specific human antibody inhibits merozoite invasion of erythrocytes
21. Identification of isolate-specific proteins on sorbitol-enriched Plasmodium falciparum infected erythrocytes from Gambian patients
22. Plasmodium falciparum: Further characterization of a functionally active region of the merozoite invasion ligand EBA-175
23. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination
24. An improved plasmid DNA expression vector for direct injection into skeletal muscle
25. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi
26. A recombinant baculovirus expressed Plasmodium falciparum receptor-binding domain of the erythrocyte binding protein EBA-175 biologically mimics native protein
27. Synthetic oligonucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
28. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acid
29. Enumeration of parasites in the blood of malarial patients
30. Characterization of the 175kDa erythrocyte binding antigen of Plasmodium falciparum
31. A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac9(alpha 2-3)Gal-sequences of glycophorin A
32. Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A
33. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite
34. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed and/or -rechallenged Aotus vociferans monkeys
35. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria
36. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys
37. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria
38. Phase I trial in humans of an oil-based adjuvant Seppic Montanide ISA 720
39. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers